Itemgroups:
Demography, Diagnosis information, days between infection and diagnosis, Disease phases at baseline and follow-up, Duration (days) of..., Follow-up duration after SARS-CoV-2 diagnosis, Last known status, Limitation of therapy during SARS-CoV-2 infection, Specialist palliative care during SARS-CoV-2 infection, Disease limiting life expectancy before positive SARS-CoV-2 testing, Comorbidities, Central nervous system / Neurological disesases, Comorbidities, Cardiovascular diseases, Comorbidities, Pulmonary diseases, Comorbidities, Hematological / oncological diseases, Comorbidities, Rheumatological diseases, Comorbidities, Allergology, Comorbidities, Other internal disorders, Comorbidities, Other conditions, Heart failure before SARS-CoV-2, NYHA classification, Body-Mass-Index (BMI), Smoking status, Use of e-cigarettes and / or vaporizer?, Treatments received, Recent immunosuppressive medication, Colonisation with multi-resistant pathogens, Complications at baseline: Thrombotic and thromboembolic manifestations, Complications at baseline: Neurological, Complications at baseline: Other severe organ damage, Complications at baseline: Other, Symptoms: Please click all symptoms which occurred in the respective clinical phase, Vital signs and respiratory parameters, Heart function: Ejection fraction (EF) at SARS-CoV-2 detection, Baseline: Chest CT results at SARS-CoV-2 detection, Cardiovascular magnetic resonance imaging (CMR) performed in any clinical phase, Neurological diagnostic in various phases, Complementary and/or integrative medicine (CIM) used in any phase, Agreement to share data for scientific purposes, Biomaterial availability for research proposes, Participation in interventional clinical trials